GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Return-on-Tangible-Asset

Pacific Biosciences of California (Pacific Biosciences of California) Return-on-Tangible-Asset : -36.46% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pacific Biosciences of California's annualized Net Income for the quarter that ended in Dec. 2023 was $-328.1 Mil. Pacific Biosciences of California's average total tangible assets for the quarter that ended in Dec. 2023 was $899.7 Mil. Therefore, Pacific Biosciences of California's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -36.46%.

The historical rank and industry rank for Pacific Biosciences of California's Return-on-Tangible-Asset or its related term are showing as below:

PACB' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -65.39   Med: -42.69   Max: 10.46
Current: -31.62

During the past 13 years, Pacific Biosciences of California's highest Return-on-Tangible-Asset was 10.46%. The lowest was -65.39%. And the median was -42.69%.

PACB's Return-on-Tangible-Asset is ranked worse than
70.17% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -2.38 vs PACB: -31.62

Pacific Biosciences of California Return-on-Tangible-Asset Historical Data

The historical data trend for Pacific Biosciences of California's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Return-on-Tangible-Asset Chart

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.87 10.46 -22.65 -29.47 -34.59

Pacific Biosciences of California Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.70 -34.80 -26.55 -26.74 -36.46

Competitive Comparison of Pacific Biosciences of California's Return-on-Tangible-Asset

For the Medical Devices subindustry, Pacific Biosciences of California's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Return-on-Tangible-Asset falls into.



Pacific Biosciences of California Return-on-Tangible-Asset Calculation

Pacific Biosciences of California's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-306.735/( (946.867+826.768)/ 2 )
=-306.735/886.8175
=-34.59 %

Pacific Biosciences of California's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-328.072/( (972.673+826.768)/ 2 )
=-328.072/899.7205
=-36.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Pacific Biosciences of California  (NAS:PACB) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Pacific Biosciences of California Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
Executives
Oene Mark Van officer: Chief Operating Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline director 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim officer: Chief Financial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel officer: See Remarks 1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer officer: Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson director 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen officer: Chief Commercial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller director 400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer officer: VP Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez director 3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston director
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein director 1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025